AnchorDx: Marina Bibikova

AnchorDx has hired Marina Bibikova as its chief scientific officer. She will be responsible for the development of early cancer detection technology, global IVD registrations, strategic partnerships with overseas firms, international patent strategy, and global commercialization acceleration. Bibikova has more than 25 years of experience in the genomics space and worked at Illumina for more than 20 years as a principal scientist. AnchorDx noted she led the submission of the Illumina MiSeqDx sequencer to the US Food and Drug Administration for clearance. The platform was the first IVD, next-generation sequencer to receive such regulatory designation.